摘要
目的探讨骨髓增生异常综合征(Myelodysplastic syndrome,MDS)患者血清β2-微球蛋白(β2-MG)水平与预后的关系。方法测定58例MDS患者治疗前的空腹血清β2-MG水平,将患者分为β2-MG≥2.0mg/L和β2-MG<2.0mg/L两组,比较两组患者的外周血白细胞计数、血红蛋白值、血小板计数和患者的生存时间。结果β2-MG水平高于2.0mg/L组的患者外周血白细胞计数、血红蛋白值、血小板计数和生存期差于β2-MG水平低于2.0mg/L组的患者。结论β2-MG水平高低与MDS患者的预后有相关性。
Objective To investigate the level of serum β2-mieroglobulin （ β2-MG） and its role in prognosis in myelodysplastie syndromes （MDS）. Methods Serum β2-MG levels were determined in 58 patients with MDS. Patients were divided into two groups according to the value of serum β2- MG level, hemoglobin level, leukocyte count and thrombocyte count was also recorded. Results An elevated β2- MG （ ≥2.0 mg/L） was found to be associated with decreased probability of survival （ P 〈 0.05 ） , it is lower in the level of hemoglobin level, leukocyte count and thrombocyte count. Conclusion Serum β2- MG levels may be helpful to know the prognosis in patients with MDS.
出处
《海南医学》
CAS
2010年第5期8-9,共2页
Hainan Medical Journal
